Letters to the Editor
January 2013

Inappropriate Data and Measures Lead to Questionable Conclusions—Reply

Author Affiliations

Author Affiliations: Departments of Medicine, Health Studies, and Psychiatry (Dr Gibbons) and Center for Health Statistics (Drs Gibbons, Brown, and Hur), University of Chicago, and Department of Psychiatry, University of Illinois at Chicago (Dr Davis), Chicago, and Center for Medication Safety, Pharmacy Benefit Management Services, Hines Veterans Affairs Hospital, Hines (Dr Hur); Prevention Science and Methodology Group, Center for Family Studies, Department of Epidemiology and Public Health, University of Miami, Miami, Florida (Dr Brown); and Department of Molecular Imaging and Neuropathology, New York State Psychiatric Institute and Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York (Dr Mann).

JAMA Psychiatry. 2013;70(1):121-123. doi:10.1001/jamapsychiatry.2013.749

In reply

We appreciate Spielmans and colleagues' interest in our article; however, their concerns about the data in our article are unfounded.

Spielmans and colleagues state that study LYAQ included atomoxetine as a treatment and should have been excluded. In fact, the first 2 active treatment visits did not include atomoxetine and our analysis of the data from this study was restricted to this period (days 1-42 postbaseline depending on the subject). Furthermore, although patients in this study had comorbidities including attention-deficit/hyperactivity disorder, the majority (81%) of patients had a depressive disorder. As such, our inclusion of this study was scientifically appropriate.

First Page Preview View Large
First page PDF preview
First page PDF preview